JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside.

JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside.

Item
http://www.wikidata.org/entity/Q38169682
Emerging treatment options for myelofibrosis: focus on pacritinibSelective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.Haematological manifestations of lupus.2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and TNew Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.JAK inhibition and progressive kidney disease.Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance.Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.The anti-apoptotic Bcl-2 family protein A1/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK/STAT signaling.Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p.The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.
P2860

JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside.

Item
http://www.wikidata.org/entity/Q38169682
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
JAK inhibition in the myelopro ...... ed from the bench and bedside.
@en
type
label
JAK inhibition in the myelopro ...... ed from the bench and bedside.
@en
prefLabel
JAK inhibition in the myelopro ...... ed from the bench and bedside.
@en
P1433
P1476
P2093
P304
P31
P356
P478
P577
P5875
P698
P356
P1433
P1476
JAK inhibition in the myelopro ...... ed from the bench and bedside.
@en
P2093
P304
P31
P356
10.1182/ASHEDUCATION-2013.1.529
P478
P577
P5875
P698